- In September 2024, the U.S. FDA approved EBGLYSS (lebrikizumab-lbkz) developed by Eli Lilly and Company for the treatment of moderate to severe atopic dermatitis (eczema) adult and children aged 12 years and above who weigh at least 40kg that is not well manage by topical treatment. This approval is expected to boost market growth.
- In August 2023, Lynk Pharmaceuticals Co., Ltd. announced positive topline results from its Phase II clinical trial of LNK01001 for adults with atopic dermatitis (AD). After 12 weeks of treatment, preliminary data indicated that patients in both the low-dose and high-dose groups demonstrated significant improvements in Eczema Area and Severity Index (EASI) scores compared to the placebo group. The successful completion of clinical trial and approval of product is anticipated to drive market growth.
- In June 2022, the U.S. FDA approved Dupixent (dupilumab) developed by Sanofi for the treatment of moderate to severe atopic dermatitis (eczema) children aged 6 months to 5 years whose disease not controlled with treatment of topical drugs. This approval is anticipated to drive market growth.
